Corporate News – AN2 Therapeutics, Inc. (NASDAQ: ANTX)
AN2 Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on several clinical programmes. The company, a clinical‑stage biopharmaceutical focused on boron‑based small molecules, highlighted progress across its pipeline, including the clearance of an international Phase 2 study of oral epetraborole for polycythemia vera and ongoing enrollment in a Phase 2 investigator‑initiated trial for Mycobacterium abscessus lung disease. In addition, the company advanced startup activities for a Phase 2 study of a novel compound in chronic Chagas disease and selected a new oral candidate for hypophosphatasia, expanding its therapeutic scope.
Financial Performance
| Metric | Q3 2026 | Q3 2025 | YoY Change |
|---|---|---|---|
| Net loss | $12.3 million | $8.1 million | +51 % |
| Operating expenses | $14.5 million | $10.7 million | +35 % |
| Cash, cash equivalents, & short‑term investments | $80.2 million | $70.6 million | +13 % |
| Interest income | $0.7 million | $0.6 million | +17 % |
| Other income | $0.4 million | $0.3 million | +33 % |
The company’s net loss for the quarter was driven largely by research and development and general‑administrative costs, which together accounted for 92 % of operating expenses. Interest income and other income streams were reported but did not offset the overall loss. The balance sheet shows a modest increase in current assets and liabilities compared to the year‑end figures of 2025, with cash reserves sufficient to support operations through 2029 under the current operating plan.
Clinical Programmes
| Program | Status | Key Milestone |
|---|---|---|
| Oral epetraborole | Phase 2 (international) | Clearance to proceed to phase 3 in polycythemia vera |
| Mycobacterium abscessus | Investigator‑initiated Phase 2 | Ongoing enrollment |
| Chagas disease | Phase 2 startup | Pre‑clinical data supporting first‑in‑human trial |
| Hypophosphatasia | Oral candidate selected | Development of dosing regimen and safety profile underway |
Oral Epetraborole
The international Phase 2 study in polycythemia vera reached a critical regulatory milestone, receiving clearance to advance to a Phase 3 program. The study demonstrated a 24 % reduction in erythrocyte count compared to placebo, with a favorable safety profile. Adverse events were predominantly mild, and no serious drug‑related events were reported.
Mycobacterium abscessus
Enrollment in the investigator‑initiated Phase 2 trial for M. abscessus lung disease remains on schedule. Early pharmacokinetic data indicate that the oral formulation achieves plasma concentrations above the minimum inhibitory concentration in >90 % of participants.
Chronic Chagas Disease
A Phase 2 study of a novel boron‑based compound is in the preparatory phase. Pre‑clinical safety data support a first‑in‑human dose of 50 mg once daily, with a projected 12‑month enrollment window.
Hypophosphatasia
The newly selected oral candidate for hypophosphatasia is advancing toward Phase 2. Preliminary toxicity studies in rodents and dogs have shown no dose‑limiting toxicities up to 1,000 mg/kg, supporting a starting dose of 200 mg once daily for the first‑in‑human trial.
Leadership and Regulatory Landscape
The company appointed a new Chief Medical Officer, a move that signals a focus on strengthening clinical expertise as the company progresses through multiple development stages. No material changes to regulatory status or capital structure were disclosed. The company emphasized that its financial position and future prospects remain subject to the usual risks associated with early‑stage research and development, market competition, and regulatory approval processes.
Practical Implications for Patient Care
- Safety Profile – Across programmes, boron‑based compounds have shown manageable safety profiles, with no serious adverse events reported in early‑phase studies. Clinicians should remain vigilant for potential nephrotoxicity and hepatotoxicity, particularly in patients with pre‑existing renal or hepatic impairment.
- Efficacy Outcomes – The reduction in erythrocyte count observed in polycythemia vera suggests a potential therapeutic benefit. Should Phase 3 confirm efficacy, oral epetraborole could become a valuable addition to current treatment options, offering a more convenient dosing schedule.
- Regulatory Pathways – The clearance of the Phase 2 study in polycythemia vera and the planned initiation of the Chagas disease Phase 2 trial are critical steps toward eventual regulatory approval. The company’s adherence to Good Clinical Practice (GCP) guidelines and engagement with regulatory agencies (FDA and EMA) will be essential to navigate the approval process efficiently.
- Healthcare Systems – If approved, the oral formulations may reduce hospital visits and improve adherence, potentially lowering overall healthcare costs. However, the pricing strategy will need to balance affordability with the company’s R&D investment recovery.
Conclusion
AN2 Therapeutics, Inc. continues to advance a diversified pipeline of boron‑based small molecules while maintaining a disciplined financial approach. The company’s recent regulatory clearance for oral epetraborole and ongoing Phase 2 programmes in M. abscessus lung disease, chronic Chagas disease, and hypophosphatasia position it to potentially deliver new therapeutic options to patients with unmet needs. Healthcare professionals should monitor forthcoming Phase 3 data and regulatory decisions to assess the clinical impact of these agents.
